All In Biotech

Drug Trial Radar · NCT01696461

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies

Last checked: Nov 20, 2026Latest source record: Sep 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

127

Actual

Start

May 2013

Primary completion

Aug 2016

Study completion Aug 2016

Sponsor

Sponsor type
Research network
Collaborators
Genzyme, a Sanofi Company; Sanofi
First posted
Oct 1, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor for this purpose.

Conditions

  • Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member
  • Acute Myelogenous Leukemia
  • Acute Lymphoblastic Leukemia
  • Myelodysplastic Syndrome
  • Chronic Myelogenous Leukemia
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Disease
  • Chronic Lymphocytic Leukemia

Interventions

  • PlerixaforDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Donors Whose Cells Were Successfully Mobilized and Collected With a Sufficient CD34+ Cell Dose Using Plerixafor as the Mobilizing Agent, Using an Intention-to-treat Analysis.Time frame: donation

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • Duke University

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • West Virginia University

    Morgantown, West Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.